Alpine Immune Sciences Inc
F:34LA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Shanxi Huaxiang Group Co Ltd
SSE:603112
|
CN |
|
Vericel Corp
NASDAQ:VCEL
|
US |
|
Krsnaa Diagnostics Ltd
NSE:KRSNAA
|
IN |
|
S
|
SRE Group Ltd
HKEX:1207
|
HK |
|
N
|
Nexstim Oyj
OMXH:NXTMH
|
FI |
|
STMicroelectronics NV
MIL:STMMI
|
NL |
|
Shenzhen AV-Display Co Ltd
SZSE:300939
|
CN |
|
Betterware de Mexico SAPI de CV
NYSE:BWMX
|
MX |
|
A
|
Advance United Holdings Inc
CNSX:AUHI
|
CA |
|
G
|
Greenworks Jiangsu Co Ltd
SZSE:301260
|
CN |
|
Rli Corp
NYSE:RLI
|
US |
|
W
|
Wiscom System Co Ltd
SZSE:002090
|
CN |
Alpine Immune Sciences Inc
Accounts Payable
Alpine Immune Sciences Inc
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Alpine Immune Sciences Inc
F:34LA
|
Accounts Payable
$4.2m
|
CAGR 3-Years
103%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Accounts Payable
$34.7B
|
CAGR 3-Years
11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
23%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accounts Payable
$715m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accounts Payable
$20.9B
|
CAGR 3-Years
137%
|
CAGR 5-Years
71%
|
CAGR 10-Years
36%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accounts Payable
$3.9B
|
CAGR 3-Years
134%
|
CAGR 5-Years
91%
|
CAGR 10-Years
48%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accounts Payable
$6.8B
|
CAGR 3-Years
126%
|
CAGR 5-Years
70%
|
CAGR 10-Years
47%
|
|
Alpine Immune Sciences Inc
Glance View
Alpine Immune Sciences Inc., a biotechnology company, stands poised at the intersection of innovation and necessity, carving its niche in the fast-paced world of immune system modulation. Founded to address the complex challenges of autoimmune inflammation and cancer, Alpine harnesses the intricate mechanisms of the immune system to develop novel therapies. The company's unique approach centers around their proprietary platform, the "Directed Evolution" technique, which enhances the body's natural defenses by evolving proteins to selectively target cells and pathways. This approach aims to balance efficacy with safety—a critical factor in immunotherapy—to not just treat but possibly transform the landscape of autoimmune and cancer treatments. In this innovative pursuit, Alpine generates revenue through a multi-pronged business model, leveraging both partnerships and proprietary product development. The company actively collaborates with big-name players in the pharmaceutical industry, securing milestone payments, and royalties that provide financial footing. Their pipeline, rich with potential candidates, further positions Alpine for future commercial success, especially as its therapies advance into later stages of clinical trials. By focusing on high-need areas and utilizing strategic collaborations, Alpine Immune Sciences is steadily building a sustainable business model while offering a beacon of hope for patients looking for more effective treatment options.
See Also
What is Alpine Immune Sciences Inc's Accounts Payable?
Accounts Payable
4.2m
USD
Based on the financial report for Mar 31, 2024, Alpine Immune Sciences Inc's Accounts Payable amounts to 4.2m USD.
What is Alpine Immune Sciences Inc's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
43%
Over the last year, the Accounts Payable growth was 145%. The average annual Accounts Payable growth rates for Alpine Immune Sciences Inc have been 103% over the past three years , 43% over the past five years .